Oncotelic Therapeutics highlights its proprietary nose-to-brain system as a breakthrough for CNS drug delivery.

Oncotelic Therapeutics Inc. announced its proprietary intranasal nose-to-brain (N2B) delivery system, which aims to overcome the blood-brain barrier challenge in treating central nervous system (CNS) diseases. This technology could accelerate the development of next-generation therapies for conditions like Alzheimer's and biodefense-related illnesses by enabling rapid and targeted drug delivery to the brain. The company is positioned among leading biopharma firms focusing on innovative therapeutic platforms in oncology and rare diseases, supported by a strong patent portfolio and joint ventures. This advancement reflects a broader industry shift emphasizing drug delivery solutions alongside drug discovery to unlock new treatment possibilities.